BACKGROUND: HLA class I molecules present antigenic peptides to cytotoxic T lymphocytes and, thus, play an important role in immune surveillance. Since 1970s there have been many reports of an increased frequency of one or more HLA haplotype in association with autoimmune disease, and malignancy. We studied types of HLA class I antigens in 204 resected non-small cell lung carcinoma (NSCLC) patients and also examined its correlation with clinicopathologic features and prognosis. METHOD: Serological typing for HLA class I antigens was performed using a microcytotoxicity test. The disease-free survival curves were calculated by the Kaplan-Meier method and then compared using the Logrank test. Multivariate analysis was carried out by Cox's proportional hazard method. RESULTS: The difference in disease-free survival time between the HLA-A2 present group and A2 absent group was significant (P = 0.040). The 3-year disease-free survival rate of all patients was 44% in HLA-A2 present group and 66% in A2 absent group. When a comparison was made within the group with stage I, expression of HLA-A2 was the only independent factor that affected survival time by multivariate analysis (P = 0.0457). CONCLUSIONS: Expression of HLA-A2 was considered as one of the unfavorable prognostic factors in NSCLC patients. Our results suggested expression of HLA-A2 in NSCLC patients was one of the mechanisms of escape from immune surveillance.
BACKGROUND: HLA class I molecules present antigenic peptides to cytotoxic T lymphocytes and, thus, play an important role in immune surveillance. Since 1970s there have been many reports of an increased frequency of one or more HLA haplotype in association with autoimmune disease, and malignancy. We studied types of HLA class I antigens in 204 resected non-small cell lung carcinoma (NSCLC) patients and also examined its correlation with clinicopathologic features and prognosis. METHOD: Serological typing for HLA class I antigens was performed using a microcytotoxicity test. The disease-free survival curves were calculated by the Kaplan-Meier method and then compared using the Logrank test. Multivariate analysis was carried out by Cox's proportional hazard method. RESULTS: The difference in disease-free survival time between the HLA-A2 present group and A2 absent group was significant (P = 0.040). The 3-year disease-free survival rate of all patients was 44% in HLA-A2 present group and 66% in A2 absent group. When a comparison was made within the group with stage I, expression of HLA-A2 was the only independent factor that affected survival time by multivariate analysis (P = 0.0457). CONCLUSIONS: Expression of HLA-A2 was considered as one of the unfavorable prognostic factors in NSCLCpatients. Our results suggested expression of HLA-A2 in NSCLCpatients was one of the mechanisms of escape from immune surveillance.
Authors: Kenneth Seier; Chaitanya Bandlamudi; Evan Rosenbaum; Mark Dickson; Mrinal Gounder; Mary L Keohan; Ping Chi; Ciara Kelly; Sujana Movva; Benjamin Nacev; Noemi Simeone; Mark Donoghue; Emily K Slotkin; Li-Xuan Qin; Cristina R Antonescu; William D Tap; Sandra P D'Angelo Journal: Clin Cancer Res Date: 2020-08-14 Impact factor: 12.531
Authors: Emilia Andersson; Lisa Villabona; Kjell Bergfeldt; Joseph W Carlson; Soldano Ferrone; Rolf Kiessling; Barbara Seliger; Giuseppe V Masucci Journal: Cancer Immunol Immunother Date: 2012-01-19 Impact factor: 6.968
Authors: Emilia Andersson; Isabel Poschke; Lisa Villabona; Joseph W Carlson; Andreas Lundqvist; Rolf Kiessling; Barbara Seliger; Giuseppe V Masucci Journal: Oncoimmunology Date: 2015-07-25 Impact factor: 8.110